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Abstract
Western blotting is a commonly used technique in biological research. A major problem with
Western blotting is not the method itself, but the use of poor quality antibodies as well as the
use of different experimental conditions that affect the linearity and sensitivity of the West-
ern blot. Investigation of some conditions that are commonly used and often modified in
Western blotting, as well as some commercial antibodies, showed that published articles
often fail to report critical parameters needed to reproduce the results. These parameters
include the amount of protein loaded, the blocking solution and conditions used, the amount
of primary and secondary antibodies used, the antibody incubation solutions, the detection
method and the quantification method utilized. In the present study, comparison of ubiquiti-
nated proteins in rat heart and liver samples showed different results depending on the anti-
body utilized. Validation of five commercial ubiquitin antibodies using purified ubiquitinated
proteins, ubiquitin chains and free ubiquitin showed that these antibodies differ in their abil-
ity to detect free ubiquitin or ubiquitinated proteins. Investigating proteins modified with inter-
feron-stimulated gene 15 (ISG15) in young and old rat hearts using six commercially
available antibodies showed that most antibodies gave different semi-quantitative results,
suggesting large variability among antibodies. Evidence showing the importance of the
Western blot buffer and the concentration of antibody used is presented. Hence there is a
critical need for comprehensive reporting of experimental conditions to improve the accu-
racy and reproducibility of Western blot analysis. A Western blotting minimal reporting stan-
dard (WBMRS) is suggested to improve the reproducibility of Western blot analysis.
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Introduction
Western blotting is a technique that was developed in 1979 [1] and is now a commonly used
technique in biomedical research. This method offers many advantages over other techniques
for detecting and semi-quantifying target proteins, allowing the detection of a single target out
of thousands of proteins as well as obtaining molecular weight information about the target
protein in the same experiment [2]. The main disadvantage of Western blotting is that this
technique requires a specific antibody to a target protein; thus many protein targets cannot be
investigated because of the lack of specific antibodies. However, the number of antibodies avail-
able for Western blotting is expanding at a rapid pace as the production costs have decreased.
A search of the internet on August 1st, 2014 showed that> 50,000 monoclonal and> 160,000
polyclonal antibodies are available from three companies for which the total number of anti-
bodies available were listed on their websites (Santa Cruz Biotechnology, Aviva Systems Bio-
technology and Abnova). The largest antibody search engine, CiteAb (www.citeab.com) has
over 2.1 million antibodies listed as of April 2015. According to the Antibody Resource website
(http://www.antibodyresource.com/onlinecomp.html), there are at least 200 companies that
sell antibodies (April, 2015). The labome website (http://www.labome.com/method/Antibody-
Companies.html) lists at least 316 companies that sell antibodies (April 2015). A major
demand for new antibodies comes from the field of proteomics, where Western blot analysis is
often used to validate differentially regulated proteins. However, the lack of highly specific anti-
bodies is a common problem [3–9].
An investigation using one of the most commonly utilized commercial antibodies for the
cannabinoid CB2 receptor showed that the common practice of only validating antibodies with
positive controls is insufficient to ensure antibody reliability [10] (S1 Table). Evaluation of nine
commercially available anti-CCR5 (CD195) monoclonal antibodies showed that three antibod-
ies displayed substantial background binding to CCR5 negative cells [11]. In an important
study that investigated more than 200 antibodies against 57 different histone modifications in
Drosophila melanogaster, Caenorhabditis elegans and human cells, more than 25% of the anti-
bodies failed Western blot or dot blot specificity tests [12]. These investigations all show that
more rigorous testing of antibodies is needed.
Western blotting itself has also gotten less expensive, allowing more labs to utilize this tech-
nique. As more labs use Western blotting, more antibodies are being purchased. While it is
now fairly straightforward to produce antibodies, determining the usefulness of each antibody
requires a significant investment of time and money, as the number of applications of an anti-
body is numerous. As such the research community has experienced substantial problems with
obtaining accurate results since most antibodies are made available for sale with limited valida-
tion. In many cases researchers must use an antibody with no reliable information regarding its
usefulness for their application. In these cases the researcher is forced to validate commercially
available antibodies for their application or generate their own antibody. Unfortunately, in our
experience> 50% of commercially available antibodies are of poor quality and should not be
utilized for semi-quantitative Western blot analysis. A survey done by 1DegreeBio of 400 anti-
body users reported that 48% of researchers found that at least half of the antibodies they pur-
chased did not work as expected (http://blog.scienceexchange.com/2012/03/guest-post-
alexandra-hodgson/). Another study done in 2008 showed that<50% of around 6,000 rou-
tinely used commercial antibodies recognized only their specified targets [13]. Although some
of the error is likely due to experimental error, a substantial proportion is due to poor quality
antibodies. Over the last few years several websites have been developed so the user community
can provide feedback about antibody quality. These websites include the antibody validation
database (http://compbio.med.harvard.edu/antibodies/), antibody advisor (http://www.
Need for Western Blotting Minimal Reporting Standard
PLOS ONE | DOI:10.1371/journal.pone.0135392 August 19, 2015 2 / 18
antibody-adviser.org/pages/home), antibodypedia (http://www.antibodypedia.com/), pAB-
mABs (http://pabmabs.com/wordpress/), and 1degreebio (http://1degreebio.org/). Unfortu-
nately, these websites have not been as helpful as expected because relatively few researchers
provide feedback, and the feedback provided is limited regarding the experimental conditions.
One way to improve the reproducibility of Western blot analysis is to improve the quality of
the antibodies. Antibodies produced in animals sometimes give questionable results. Small
scale experiments have suggested that recombinantly produced antibodies would improve
reproducibility [14]. Pilot programs initiated in 2010 by the US National Institutes of Health
(NIH), the Protein Capture Reagents Program, and by the European Union (EU), called Affi-
nomics, have made attempts to scale up recombinant technologies, including recombinant
antibodies that would help improve reproducibility [15]. However, this will take considerable
time, and even when recombinant antibodies are available for most targets, other factors that
affect the reproducibility of Western blot analysis still need to be taken into account. These fac-
tors include loading too much protein on polyacrylamide gels, using un-optimized buffers or
blocking reagents, and lack of proper controls. Therefore, a major problem with Western blot-
ting is not the method itself but the use of sub-standard antibodies and sub-standard tech-
niques. To determine all the problems that exist and the best solutions, detailed information in
publications are needed. The lack of Western blotting information present in journal articles
currently prevents researchers from reproducing original results and does not prevent poor
quality antibodies from being used by other laboratories. In some published papers the lack of
reporting standards is apparent, as evident by the failure of researchers to perform proper con-
trols and/or replicates and the failure of reviewers to request this information.
Currently, there is clearly a need for comprehensive reporting of experimental conditions,
not only to improve reproducibility but also to reduce the cost of Western blotting. As more
researchers report antibody catalog numbers and blotting conditions, better antibodies will be
identified and used more often, while poor quality antibodies will be used less frequently, and
other researchers will be able to utilize protocols that work well for specific antibodies.
In this article we provide experimental evidence for the need of a Western blotting minimal
reporting standard (WBMRS) in all publications using Western blotting. The new information
will only add about 100 words to a manuscript but will have a tremendous impact on improv-
ing Western blot analysis. Since a few previous reports have suggested that commonly used
antibodies give artifactual Western blotting signals [4, 5] we hypothesized that inaccuracies in
Western blot analysis would be more prominent with antibodies to more complex epitopes
such as post-translational modifications (PTMs). Our investigation suggests that the problem
of artefactual signals observed with some antibodies directed against a single target is also
observed when using antibodies directed against an epitope found on multiple targets (such as
ubiquitination and ISGylation). Experimental data also suggest that besides the quality of the
antibody, other commonly modified steps used in Western blotting also significantly alter the
results obtained. Overall our results strongly suggest that there is an urgent need for compre-
hensive reporting of experimental conditions to improve Western blot analysis.
Materials and Methods
Materials
Urea, DTT, and buffer reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Purified ubiquitin (BML-UW8795), ubiquitin chains (BML-UW0825), and MG-132
(BML-PI102) were obtained from Enzo Life Sciences (NY, USA).
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Cell Culture
H9c2 rat cardiac cells (ATCC, CRL-1446) were grown in DMEM (Invitrogen, Carlsbad, CA) in
the presence of 5% FBS and 0.5% Penicillin/Streptomycin (Invitrogen) in a humidified incuba-
tor at 37°C and 5% CO2. The proteasome inhibitor MG132 (10μM final concentration) was
added to the growth media and samples collected 36 h after treatment.
Sample Preparation
Male mice were euthanized at 3 months of age by inhalation of 3% isoflurane and subsequent
cervical dislocation. Hearts were removed, washed in cold PBS, weighed, and flash frozen. This
method has been demonstrated to be excellent for investigation by Western blotting [16]. Male
Fisher 344-Brown Norway rats (young (10 month old) and old (30 month old)) were assigned
to one of two experimental groups: normal or hindlimb-suspension groups. It has been previ-
ously shown that 14 days of hindlimb suspension increases the predisposition of rats to get car-
diac arrhythmias, while 21 days of hindlimb suspension significantly decreases the turnover
rates of cardiac muscle proteins [17, 18]. It is possible that ISGylation would be affected in
hearts from hindlimb suspended animals since some of the enzymes that promote ISGylation
are also involved in ubiquitin conjugation [19]. To determine if the levels of ISGylated proteins
(proteins which are covalently linked to ISG15) in hearts were affected by unloading of the
lower limb muscles the noninvasive tail suspension model was utilized [20]. The rats were
maintained in head-down tilt position with their hindlimbs suspended for 14 days. Hearts
were collected after rats were anesthetized with isoflurane gas. After tissue removal was com-
pleted, the rats were killed by exsanguination. Hearts were weighed, frozen in liquid nitrogen,
and stored at -80°C for later analysis. This investigation was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. All animal procedures were approved by the University of Cali-
fornia, Davis Institutional Animal Care and Use Committee and all efforts were made to mini-
mize suffering.
Preparation of Purified Polyubiquitinated Proteins and Lysate without
Ubiquinated Proteins
Rat cardiac H9c2 cells were exposed to 10μMMG-132 (a proteasome inhibitor) for 36 h to
drastically increase the levels of ubiquinated proteins. Samples were then sonicated in 50 mM
Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, and protease inhibitors
(P2714, Sigma) at 4°C. After centrifugation (14,000xg) for 10 min at 4°C, the supernatant was
incubated with Tandem Ubiquitin Binding Entities (TUBEs) bound to agarose (TUBE2-agar-
ose) (UM402, obtained from LifeSensors, PA, USA). TUBEs display a significantly higher
increase in affinity for polyubiquitin moieties (up to 1000-fold) over the single ubiquitin bind-
ing associated domain (UBA) [21]. For every mg of total protein, 25 μl of resin was utilized and
incubated for 1 h at 4°C with rocking. TUBE-agarose was collected by low speed centrifugation
(1000xg, 4°C) for 2 min. The beads were washed with Tris-buffered saline containing 0.05%
Tween-20 (TBST) and collected by low speed centrifugation. Washing was repeated three
times and the polyubiquinated proteins eluted with 0.2 M glycine HCl, pH 2.5 (3X total volume
of pelleted resin) for one 1 h at 4°C. Beads were removed by centrifugation at 10,000xg for 5
min. The eluted polyubiquitinated proteins were quantified, mixed with Laemmli sample
buffer and heated at 95°C for 5 min.
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Preparation of Cytosolic Cardiac and Liver Homogenates
Pulverized rat heart or chopped mouse heart or rat liver tissue was homogenized in cold
homogenization buffer (50 mM Tris, 1 mM EDTA, 150 mMNaCl, 5 mMMgCl2, 0.5 mM
DTT, pH 7.5) with a glass dounce homogenizer (25 strokes), and the homogenates were centri-
fuged at 12,000xg and 4°C for 30 min. The supernatants were removed, diluted to equal protein
concentrations, combined with 4X SDS sample buffer (8% SDS, 40% glycerol, 0.4% bromophe-
nol blue, 5% β-mercaptoethanol, 240mM Tris, pH 6.8), and boiled 4 min at 95°C.
Protein Concentration Determination
The protein concentrations of cytosolic cardiac homogenates were determined with a Nano-
drop 2000c (Thermo Scientific). The Nanodrop is the preferred method for determining the
concentrations of cytosolic fractions since nucleic acid contamination, which affects the absor-
bance values on a Nanodrop, is usually absent in these samples.
Western Blot Analysis
Protein samples (20 μg/well) and dual plus molecular weight ladders (#161–0374, Bio-Rad Lab-
oratories, Hercules, CA) were separated by SDS-PAGE on Criterion Stain-free and conven-
tional Precast Gels with a 4–15% gradient (Bio-Rad) for approximately 60 min at 150V in
running buffer (25 mM Tris base, 192 mM glycine, 1% SDS, pH 8.3). Stain-free gels were acti-
vated by exposure to UV for 1 min. Proteins were transferred to nitrocellulose membranes
(#170–4159, Bio-Rad) using the Bio-Rad Trans-Blot Turbo Transfer System for 7 min. Total
proteins on membranes were detected using the Stain-free method [22, 23] or with ponceau S
staining. All Western blotting procedures were carried out at room temperature with agitation
except when stated otherwise. Membranes were blocked with 3% non-fat milk (# 170–6404
Bio-Rad) in TBST (20 mM Tris, 150 mM NaCl, containing 0.05% Tween-20, pH 7.4) or PBST
(10 mM phosphate, 137 mM NaCl, 2.7 mM KCl, containing 0.05% Tween-20, pH 7.4) for 60
min. Membranes were then incubated with primary antibodies (see Table 1) in TBST or PBST
with 1% non-fat milk at room temperature for 2 h or at 4°C overnight. Removal of excess pri-
mary antibody was carried out by washing the membranes in TBST or PBST three times for 5
min each. The secondary antibody (peroxidase-conjugated anti-mouse, anti-goat, or anti-rab-
bit IgG secondary antibody (anti-mouse Cat. # A9044, anti-goat #A5420, anti-rabbit Cat.
#A0545, Sigma-Aldrich, St. Louis, MO, USA)) diluted 1:5000 was incubated with the mem-
brane in TBST or PBST with 1% non-fat dry milk for one h at room temperature. Excess sec-
ondary antibody was removed by washing the membranes in TBST or PBST three times for 5
min each. Membranes were exposed to Clarity enhanced chemiluminescence (ECL) reagent
(Cat. # 170–5061, Bio-Rad) for 2 min at room temperature and visualized using a ChemiDoc
MP (Cat. # 170–8280, Bio-Rad). Detection and quantification of band intensities was con-
ducted using Image Lab 5.0 software (Bio-Rad). Bands were normalized to total protein by
dividing the intensity of the band by the intensity of the total protein from the same sample on
the same blot. Background correction was carried out as described by Taylor et al. [24]. At least
three biological replicates were used for young and old rat studies while at least three technical
replicates were used for the heart and liver comparisons.
Statistics
The results are shown as mean ± standard deviation (SD). Statistical significance was deter-
mined by student’s t-test or one-way ANOVA. Comparisons yielding a value of p< 0.05 were
regarded as statistically significant.
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Results and Discussion
Western blotting is a powerful technique for quantifying protein levels; however it is often not
well optimized and relies greatly on antibodies which are poorly validated. As our study sug-
gests, antibodies differ in regards to the optimal blotting conditions and results they yield; even
different antibodies to the same target peptide can give different results. Currently more poly-
clonal antibodies are used for Western blotting than monoclonal antibodies, mainly due to the
ease and lower up-front cost of making polyclonal antibodies. However, polyclonal antibodies
vary from lot to lot due to different animals, improper storage, and different bleeds from an
individual animal. Since the previously mentioned studies in S1 Table as well as other studies
have shown that some popular antibodies to specific proteins show artifactual signals [3–5], we
investigated two sets of antibodies to common PTM epitopes associated with ISGylated and
ubiquitinated proteins.
Comparison of Ubiquitin Antibodies
Ubiquitin antibodies have been developed to target free ubiquitin, ubiquitin chains linked in a
specific manner, or ubiquitin in any form. Depending on the quality and specificity of the ubi-
quitin antibody used, different researchers may obtain different results when examining ubi-
quitination or free ubiquitin levels. Our objective was to compare ubiquitin blots using five
different antibodies to see if they gave similar results. It was expected that most anti-ubiquitin
antibodies would detect high molecular weight polyubiquitinated proteins in the heart and
liver samples as well as the polyubiquitinated protein-enriched lysate. It was also expected that
the main polyubiquinated proteins detected would be similar to other anti-ubiquitin
antibodies.
Comparison of the mouse heart and liver cytosolic fractions (20 μg each) using five com-
mercially available antibodies showed that three antibodies identified consistent major bands
at approximately 26 and 60 kDa (Fig 1). These antibodies were utilized under the same condi-
tions (1:1000 dilution) except for the last two lanes on the right which were at 1:100 and 1:2000
Table 1. Table showing the primary antibodies used and basic information about these antibodies.
Antibody
Target
Antibody Name/ catalog #/
lot number
Supplier Type of Antibody/concentration of antibody
as reported by manufacturer
Citations on manufactur-er’s
website/ citations on CiteAb *
Ubiquitin VU1-ubiquitin/VU101 LifeSensors Monoclonal/0.5mg/mL in PBS 0/0
Ubiquitin/U5379/089K6001 Sigma Rabbit Polyclonal/NR 26/36
Ubiquitin/AP1228a/RB0643 Abgent Rabbit Polyclonal/NR 1/1
P4G7-H11/ADI-SPA-203-D Enzo Monoclonal/NR 1/0
FK1/PW8805 Enzo Monoclonal/0.5mg/mL in PBS 24/9
ISG15 H150/sc-50366/A0509 Santa Cruz Rabbit polyclonal/ 200μg/mL in PBS 8/7
R140/sc-50368/E0107 Santa Cruz Rabbit polyclonal/ 200μg/mL in PBS 0/1
M20/sc-18421/B0613 Santa Cruz Goat polyclonal/ 200μg/mL in PBS 0/0
F9/sc-166755 Santa Cruz Monoclonal/200μg/mL in PBS 0/0
E9/sc-166794 Santa Cruz Monoclonal/200μg/mL in PBS 0/0
ISG15/14-5857 EBioscience Monoclonal/500μg/mL in aqueous solution 5/5
β-Actin β-Actin/sc-47778 Santa Cruz Monoclonal/200μg/mL in PBS 565/715
PSMA6 PSMA6/ab109377/
YH120115
Abcam Rabbit Monoclonal/ NR 1/1
NR, Not reported.
* Number of publications using these antibodies that are listed on the manufacturer’s website and on CiteAb website as of July 1st 2015.
doi:10.1371/journal.pone.0135392.t001
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dilutions (Fig 1). Two antibodies (VU101 and P4G7-H11) detected a large number of high-
molecular weight ubiquitinated proteins while another antibody (U5379) detected some high
molecular weight bands. However, only one antibody (VU101) detected free ubiquitin in the
liver samples under the conditions investigated (the location of free ubiquitin is shown by an
arrow in Fig 1). Four antibodies showed higher levels of ubiquinated proteins in heart than
liver for the same amount of total protein. The antibody that did not show more ubiquitination
in heart (AP1228a) detected no proteins in the heart sample and only one protein in the liver
sample. Although two antibodies, VU101 and FK1, gave similar results, the FK1 antibody did
not detect high molecular weight proteins. Since the manufacturer recommends the FK1 anti-
body be utilized in BSA instead of nonfat milk (NFM), Western blot analysis using FK1 was
also carried out using 1% BSA in TBST (lane FK1 in Fig 1). All the other blots were carried
out using NFM. When BSA was used instead of NFM a few additional bands were detected.
Since antibody concentration is also important, all antibodies were utilized at the dilution
that was recommended by the manufacturer. The antibodies VU101, AP1228a, P4G-H11, and
FK1 are all recommended for use at 1:1000 while U5379 is recommended at a concentration of
1:100. Varying the concentration of U5379 from 1:100 to 1:2000 showed the importance of the
concentration of antibody used, as the 1:2000 dilution only faintly detected one high molecular
weight band in the liver sample. However, independent of blocking reagent used or
Fig 1. Comparison of anti-ubiquitin antibodies. Heart and liver lysates (20 μg each) were investigated byWestern blotting using five commercially
available anti-ubiquitin antibodies (VU101, U5379, AP1228a, P4G7-H11, FK1). Arrow shows location of free unbound ubiquitin. Stain-free staining of total
proteins loaded was used as the normalization control. H, heart; L, liver. BSA was used as the blocking reagent for the blot labeled FK1* while non-fat milk
was used as the blocking reagent in all the other blots shown. All antibodies were used at a dilution of 1:1000 except for blots labeled U5379* and U5379^
which were used at dilutions of 1:100 and 1:2000 respectively.
doi:10.1371/journal.pone.0135392.g001
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concentration of antibody, the results suggest that different anti-ubiquitin antibodies give dis-
tinctly different banding patterns when using Western blot analysis.
Further validation of these antibodies showed that one of these antibodies (AP1228a) did
not recognize either free ubiquitin or polyubiquitinated proteins (Fig 2). FK1 only recognized
one of the polyubiquitin chains and did not recognize free ubiquitin under the conditions uti-
lized (Fig 2). Purified ubiquitin was used as the positive control for free ubiquitin, while com-
mercially obtained polyubiquitin chains (tri-ubiquitin, penta-ubiquitin and octa-ubiquitin
chains) were used as a positive control for polyubiquitin chains. Purified polyubiquitinated
proteins and lysate depleted of polyubiquitinated proteins were made in our laboratory using
TUBEs. TUBEs has been shown to be highly efficient at removing polyubiquinated proteins
from lysates [25]. Two steps were taken to ensure the lysate was depleted of ubiquitinated pro-
teins: significantly more bait (TUBEs) was used than required, and the lysate remaining after
the ubiquinated proteins were removed was further processed with TUBEs to remove any trace
amounts of ubiquinated proteins. Use of the different controls showed that the VU101 anti-
body was the best antibody for detection of free ubiquitin and polyubiquitinated proteins.
Due to the relatively low amounts of polyubiquitin chains (300 ng) and purified ubiquitin
(1 μg) used, no protein bands were detectable by total protein staining methods such as Stain-
free (Fig 2). Stain-free works by cross-linking a fluorescent adduct to tryptophan residues, so
the Stain-free method will not detect the tryptophan-less ubiquitin [22]. The VU101 antibody
was able to detect all three polyubiquitin chains, the purified ubiquitin, and numerous proteins
in the purified polyubiquitinated samples, while detecting only free ubiquitin in the polyubi-
quinated protein depleted samples. TUBEs do not bind free ubiquitin with high affinity so free
ubiquitin was expected to be present in the polyubiquinated protein-depleted fractions. In the
experiments shown in Fig 1 the VU101 was used without glutaraldehyde pretreatment. The
manufacturer’s protocol for VU101 suggests for optimal results the membrane should be pre-
treated with 0.5% glutaraldehyde (Fig 2). Although VU101 recognized all the positive controls
without pre-treatment, inclusion of the 0.5% glutaraldehyde pre-treatment increased the signal
intensity of free ubiquitin and polyubiquitinated proteins. Inclusion of 0.5% glutaraldehyde
pre-treatment in the protocol for Western blotting using other anti-ubiquitin antibodies
resulted in no bands being detected, suggesting that the pre-treatment affects the antibody-
antigen interactions (data not shown).
For both VU101 and U5379, ubiquitin dimers were also detected. Non-covalent dimeriza-
tion of free ubiquitin has been previously described [26]. Of concern is that the AP1228a anti-
body detected a major band in the lysates from which polyubiquitinated proteins were
removed. While this antibody detected the octa-ubiquitin chain it did not detect the tri- and
penta-ubiquitin chains, the polyubiquitinated proteins in the polyubiquitinated enriched
lysate, or free ubiquitin. It is possible that the protein detected by AP1228a is a monoubiquiti-
nated protein still present in the polyubiquitinated depleted lysate. P4G7 detected two of the
polyubiquitinated chains, free ubiquitin and polyubiquitinated proteins in the polyubiquiti-
nated enriched lysate, suggesting that it is also a good antibody with the limitation that it does
not recognize all polyubiquinated chains. The U5379 showed reactivity to two of the polyubi-
quinated chains, but also detected some proteins in the polyubiquinated depleted lysate. The
VU101, which was the best anti-ubiquitin antibody according to our results, had fewer cita-
tions than four of the other anti-ubiquitin antibodies (Table 1). These results suggest that using
different antibodies to examine ubiquitination may give contradicting results, as each antibody
recognized different subsets of proteins, with some anti-ubiquitin antibodies not recognizing
polyubiquitinated standards and at least one antibody recognizing a potentially non-ubiquiti-
nated target. Interestingly, the most commonly cited antibody in CiteAb is the anti-ubiquitin
antibody U5379 from Sigma Chemical Company, while the best performing antibody VU101
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had no references on CiteAb. The results from four of the antibodies tested suggest that 20 μg
of mouse heart contains more polyubiquinated proteins than 20 μg of mouse liver. The anti-
ubiquitin antibody U5379 showed distinct target binding properties compared to any of the
other anti-ubiquitin antibodies. VU101, P4G7-H11 and FK1 antibodies all detected two major
polyubiquitinated proteins at 25 and 58 kDa while the U5379 antibody did not detect either of
these bands (Fig 1). While the U5379 antibody clearly detects polyubiquinated proteins (Fig 2),
this antibody also detected proteins in the polyubiquinated protein depleted lysate suggesting
that this antibody could potentially be recognizing non-ubiquitinated proteins. It is also possi-
ble that U5379 may be detecting monoubiquinated proteins in the polyubiquinated protein
depleted lysate. The potential detection of some non-ubiquitinated proteins may account for
the significantly different target protein identification obtained with this antibody compared to
the other antibodies. A possibility also exists that the tri-, penta, and octa-polyubiquinated
chains may be forming dimers which would further complicate the analysis of the Western
blots. These results emphasize that the most popular antibody is not necessarily the best anti-
body for the target protein(s).
Fig 2. Validation of anti-ubiquitin antibodies. VU101 in the presence and absence of 0.5% glutaraldehyde pre-treatment, U5379, AP1228a, or P4G7-H11
were used to detect ubiquitin and ubiquitinated proteins. A) Western blot of polyubiquitin chains (Ub3, Ub5, Ub8) (lane A), purified ubiquitin (lane B),
polyubiquitinated proteins from H9c2 cells treated with 10μMMG-132 for 36 h obtained from affinity purification using TUBEs (lane C), and unbound fraction
from H9c2 cells after removal of polyubiquitinated proteins (lane D). B) Upper figure, Western blot of free ubiquitin (lane A) and polyubiquitin chains (lane B)
with U5379 antibody diluted at 1:100 and 1:2000. Lower figure, Western blot of free ubiquitin (lane A) and polyubiquitin chains (lane B) with FK1 antibody
diluted at 1:1000 in BSA. Even when the blots were imaged for long time periods no additional bands were seen.
doi:10.1371/journal.pone.0135392.g002
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Based upon the results obtained it is recommended that positive controls should be included
whenWestern blot analysis is carried out using anti-ubiquitin antibodies. It is in the interest of
the scientists working in this field to establish what the best optimal controls would be.
Comparison of ISG15 Antibodies
ISG15 is another small protein modifier that can be conjugated to proteins to regulate their
activity. Proteins which are covalently linked to ISG15 are referred to as ISGylated proteins.
The effect of aging or skeletal muscle disuse on ISGylated protein levels in hearts has not been
previously reported. To investigate this, we initially utilized two antibodies against ISG15 and
expected to find that one antibody would detect more ISGylated proteins than the other anti-
body but that both antibodies would detect the same main ISGylated proteins. However, we
obtained significantly different results for the two antibodies by Western blot analysis. Further
investigation of five anti-ISG15 antibodies from Santa Cruz and one from eBioscience showed
that only two of these antibodies gave similar results (Fig 3). E9 and ISG15 antibodies from
Santa Cruz and eBioscience respectively (both monoclonal) gave similar results. The samples
that were investigated were young and old hearts from normal (control) and hind-limb sus-
pended (HLS) rats. The most common major bands recognized in these samples were 25 and
50 kDa bands which were identified by three antibodies tested. The other most common bands
were 37, 42, and 100 kDa which were recognized by two antibodies each. The H150 antibody
was the only antibody that recognized a 260kDa protein band. This H150 antibody which gave
different results from every other anti-ISG antibody investigated is currently the most cited
anti-ISG15 antibody (Table 1). Validation of these ISG15 antibodies was not carried out,
because we were unable to enrich for ISGylated proteins without using antibodies, and ISG15
siRNA was only able to reduce ISG15 levels by 80% in C2C12 skeletal muscle cells. Quantifica-
tion of the results to determine if old rat hearts have similar, lower, or higher levels of ISGylated
proteins than young hearts showed that three antibodies detected higher levels of ISGylated
proteins in old hearts when compared to young hearts, while four other antibodies showed no
statistically significant change (Fig 3B). One antibody (H150) showed increased ISGylated pro-
tein levels in young HLS hearts when compared to young hearts while other antibodies showed
similar ISGylated protein levels in these hearts. The eBioscience anti-ISG15 antibody showed
higher ISGylated protein levels in old HLS hearts when compared to young HLS hearts, while
the other six antibodies showed similar protein levels in HLS hearts. These results strongly sug-
gest that different ISG15 antibodies recognize different epitopes and give different results.
The results of our investigation of anti-ISG15 antibodies were more complicated than the
ubiquination results, as five of the six antibodies detected different proteins. The most cited
anti-ISG15 antibody on CiteAb was H150, and the second most cited was anti-ISG15 from
eBioscience. Both of these antibodies give distinctively different banding patterns. Bands at 37
and 100 kDa detected by at least two other antibodies were not detected by either H150 or
eBioscience anti-ISG15. The H150 antibody showed a>2.5 fold increase in ISGylated protein
levels (mainly due to a 260kDa protein) in young HLS hearts when compared to young hearts
while the anti-ISG15 from eBioscience showed no such change. These results show that
depending on the ISG15 antibody used, different results can be obtained. Hence it is critical to
have the catalog number of the antibody used in all publications. The ratio of sub-standard
antibodies to quality antibodies is likely to increase, as the number of post-translational modifi-
cation (PTM) specific antibodies is increasing at an exponential rate. Antibodies are now avail-
able for many PTM sites including acetylation, methylation, and the more common
phosphorylation sites, but many of these PTM specific antibodies do not work well. An addi-
tional complication is that the antibody specificity may change under different experimental
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Fig 3. Comparison of anti-ISG15 antibodies. (A) Seven anti-ISG-15 antibodies were used to detect the levels of ISGylated proteins in four different types of
samples. (B) Quantification of ISG15Western blots. Young, 10 month old hearts; Young HLS, high-limb suspended 10 month old hearts; old, 30 month old
hearts; Old HLS, high-limb suspended 30 month old hearts. * p < 0.05, ** p < 0.01 by 1-way ANOVA.
doi:10.1371/journal.pone.0135392.g003
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conditions and in different tissues [27]. An antibody may work well for one cell type or species
but not for other cell types.
Even if the scientific community is able to generate quality monoclonal antibodies or
recombinant antibodies for Western blotting, other factors important for the Western blotting
technique also need to be taken into account. One example is the primary antibody concentra-
tion. The amount of antibody that should be utilized for Western blotting depends on many
factors including the concentration of the enzyme, the abundance of the target protein and the
detection system used. The specificity and high affinity of antibodies for their targets allows
antibodies to be used in low concentrations (ranging from 1:100 to 1:500,000 for a 1mg/ml
starting concentration). The optimal dilution of the primary antibody has to be determined
experimentally. In general lower amounts of antibody result in increased specificity for the tar-
get protein. Using lower amounts of antibody also reduces cost.
Overall, similar to the anti-ubiquitin antibodies, proper Western blot analysis using anti-
ISG15 requires proper controls. An ISG15 knock-out mouse is available and tissues from this
mouse model would be an excellent negative control for anti-ISG15 antibodies. It may be time
for NIH to start a resource center with tissues from knock-out animal models that could be
used as negative controls for Western blot analysis. Including information in manuscripts
about controls or validations done using antibodies not previously validated would give review-
ers greater confidence in the results and would also be beneficial to other researchers [2, 28].
Effect of Primary Antibody Dilution onWestern Blotting Results
Since other factors are also important for Western blotting accuracy and reproducibility, we
investigated two of these important factors which are often overlooked: 1) the effect of primary
antibody dilution on signal detected and 2) the effect of the main buffer used in Western blot-
ting on signal detection. Different concentrations of rat liver lysates were probed with different
dilutions of anti-β-actin and anti-PSMA6 to determine the effect of antibody dilution on signal
detection. β-actin is a commonly used Western blotting normalization control and PSMA6 is a
subunit of the proteasome. While it was expected that lower concentrations of antibody (higher
dilutions) would result in lower signal intensity, we observed that anti-β-actin dilution did not
significantly affect the signal intensity detected (Fig 4E). This was surprising since a 1:25000
dilution of the anti-β-actin gave similar results to a 1:1000 dilution. Using this 25 fold dilution
of anti-β-actin would significantly reduce the cost of the Western blot without compromising
the sensitivity of detection.
In contrast, higher concentrations of anti-PSMA6 (1:5000) gave higher signal intensities of
PSMA6 when compared to lower concentrations of the anti-PSMA6 at all liver lysate amounts
investigated (Fig 4B, not normalized data). When normalized to total protein loaded it is
expected that all the protein concentrations and antibody dilutions would give a normalized
value of 1 as observed for β-actin (Fig 4F). However lower concentrations of anti-PSMA6
resulted in lower normalized signal intensities at 3 and 6 μg of liver lysate (Fig 4C). Also of sig-
nificance is that the normalized values for 12μg of lysate was statistically significantly higher
than for 3μg of lysate when the anti-PSMA6 was used at its highest concentration (1:5000 dilu-
tion, Fig 4C). This suggests that to achieve optimal results with antibodies such as the anti-
PSMA6 antibody used in these studies (as opposed to the β-actin antibody used in these stud-
ies), it is important that the amounts of proteins loaded on a gel be similar in each lane. In con-
trast to the PSMA6 antibody, using higher amounts of the β-actin antibody did not increase
the signal intensity, suggesting that for certain antibodies it is not advantageous to use higher
amounts of antibody (Fig 4E). These results show that the amount of protein loaded on a gel is
Need for Western Blotting Minimal Reporting Standard
PLOS ONE | DOI:10.1371/journal.pone.0135392 August 19, 2015 12 / 18
important, and each gel lane should have very similar total protein amounts to avoid artefacts
due to protein loading.
Effect of buffer on western blotting results. A variety of Western blotting buffers are cur-
rently used and range from TBS or PBS without any additives to TBS and PBS with several
additives including Tween-20 and low amounts of blocking reagent such as non-fat milk. TBS,
however, a commonly used buffer for Western blots, is not always the best buffer for certain
antibodies. Commercial preparations of TBS can also be different in the concentration of Tris
present and the pH of the solution. We carried out a Western blot on rat liver lysates with the
PSMA6 and β-actin antibodies using TBST or PBST to see if varying the buffer affected our
results (Fig 5). Although some researchers utilize PBS while other utilize TBS we expected that
these buffers would result in different target protein signal intensities. While anti-PSMA6 anti-
body showed similar normalized relative amounts of detected targets in different amounts of
rat liver lysates (3–12μg), anti–β-actin showed a greater than 10 fold increase in intensity when
PBS was used instead of TBS. When low abundance targets are being detected, 10 fold differ-
ences in the detection signal could be the difference between detecting the protein of interest
Fig 4. Effect of antibody concentration on linearity of target proteins detected byWestern blotting. (A) Western blot of rat liver samples (3–12 μg)
using anti-PSMA6 at four different concentrations (1:5000, 1:10000, 1:20000, and 1:50000). (B) Quantification of anti-PSMA6Western blots without including
any normalization. (C) Quantification of anti-PSMA6Western blots using total protein normalization. (D) Western blot of rat liver samples (3–12μg) using anti-
β-actin at four different concentrations (1:1000, 1:2500, 1:10000, and 1:25000). (E) Quantification of anti-β-actin Western blots without including any
normalization. (F) Quantification of anti-β-actin Western blots using total protein normalization. * p < 0.05 by 1-way ANOVA.
doi:10.1371/journal.pone.0135392.g004
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and not detecting the protein. These results show that the choice of buffer is very important for
signal intensity when certain antibodies are used. It is recommended that Western blot analysis
using uncharacterized antibodies be carried out with both PBS and TBS to determine if one
buffer is significantly superior to the other buffer.
Other Western Blotting Concerns
Several other commonWestern blotting problems exist; however since experimental data from
different laboratories including our laboratory are already available on this topic these prob-
lems are only briefly mentioned [29–35]. A common problem in Western blotting is the total
amount of protein in each well is too high. When a protein of interest is expressed at very low
amounts, some labs use very high protein loads (>60μg of total protein) to be able to detect the
protein and use a housekeeping protein (which is usually expressed at relatively high levels) as
a loading control. While the protein of interest may be in the dynamic range of the tissue or
sample being investigated, housekeeping proteins because of their abundance have a limited
dynamic range and are not linear at high protein concentrations [33]. Another problem with
blotting high amounts of proteins is the increased chance of artifacts due to non-specific bind-
ing of the antibody utilized. Using lower amounts of protein for Western blotting has been
shown to improve the detection of some poorly expressed proteins [30, 31]. The secondary
antibody used also affects the signal intensity of the target protein. IgG subclass specific sec-
ondary antibodies were found to be superior to anti-mouse IgG (H+L) antibodies in immuno-
histochemistry andWestern blotting [36]. A recent publication also showed results which
Fig 5. Effect of buffer reagent onWestern blotting linearity. (A) Western blot of rat liver samples (3–12 μg) using anti-PSMA6 and different buffers (TBST
and PBST). (B) PSMA6 quantification, not normalized to total protein. (C) PSMA6 quantification, normalized to total protein. (D) Western blot of rat liver
samples (3–12 μg) using anti-β-actin and different buffers. (E) β-actin quantification, not normalized to total protein. (F) β-actin quantification, normalized to
total protein. * p < 0.05, ** p < 0.01 by 1-way ANOVA.
doi:10.1371/journal.pone.0135392.g005
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demonstrated that the current lack of established procedures in densitometry results in inaccu-
rate quantification of many Westerns [34].
All of these reports suggest that the current standards for reporting Western blots are inade-
quate. A requirement by journals for researchers to deposit detailed antibody information into
one of the online databases would be very beneficial, but the best solution would be an NIH
mandated depositing of detailed Western blotting data into one site for all NIH funded
research. A repository with the tissue used and optimized buffer for antibodies would be espe-
cially useful to all research labs using this technique. Like polymerase chain reaction and mass
spectrometry data, reporting minimal standards are needed for Western blotting. A 10 point
requirement referred to as the Western blotting minimal reporting standard (WBMRS) is sug-
gested (Table 2 and S1 text). With limited research funding, identifying poor quality antibodies
and poor Western blotting techniques will save money, save researchers time and improve the
quality of the results.
Table 2. Western Blotting Minimal Reporting Standard (WBMRS).
Point Needed Reason
1) The primary and secondary antibodies used,
the catalog number, company purchased from,
and lot number if it is a polyclonal antibody.
Possibly by recognizing alternatively spliced
variants, PTM configurations etc. In a few cases
antibodies can recognize non-specific bands
around the molecular weight of the target protein.
Different antibodies to the same protein can give
different results. Currently more polyclonal
antibodies are used for Western blotting but vary
from lot to lot due to different animals, improper
storage, and different bleeds from individual
animals.
2) Molecular mass of band of interest should be
shown on the blot.
Several antibodies recognize bands which are
not the proper molecular masses of the target
protein. In fact some antibodies that are known
to recognize only a different molecular weight
protein are sold by some companies.
3) The amount of total protein loaded onto the gel
and the method used to determine the protein
concentration should be stated.
Use of too much protein results in inaccurate
quantification.
4) Type, amount and extent of use of blocking
reagent.
The type and amount of blocking reagents can
significantly affect the number of non-specific
bands detected by an antibody.
5) Washing solution used, how often and for how
long.
The buffer used and amount of washing affects
the background membrane staining and
sometimes the number of non-specific bands
detected by an antibody.
6) Amount and incubation time of primary
antibody. Primary antibody buffer.
The primary antibody amount and buffer it is
diluted in are critical for good Western blots.
7) Amount and time of incubation of secondary
antibodies. Secondary antibody buffer.
The secondary antibody amount and buffer used
is important for good Western blots.
8) How the image was collected. If X-ray film was used then the source of X-ray
film is needed. X-ray film has lower linearity than
commercial imagers.
9) The reagent used for detection and how long
the membrane was incubated in the reagent
(including company that manufactured the
reagent).
Different ECL reagents typically have distinct
properties. Different fluorescent secondary
antibodies also sometimes have dissimilar
properties.
10) The software (including company that created
the program and version number) used for data
analysis. Basic information about how the
quantification was carried out.
If quantification is incorrectly done then no
matter how well the Western blot was carried out
the data from the Western blot will be inaccurate.
doi:10.1371/journal.pone.0135392.t002
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Conclusion
Being able to trust the experimental data is critical for experimental research. More detailed
Western blotting information will allow some experienced reviewers to detect Western blotting
problems before manuscripts are published. Having access to more detailed Western blotting
methods is also critical for future advancements since the amount of poor quality Western data
in the literature is likely to be understated. Although the suggested WBMRS documentation
will allow other researchers to better reproduce and confirm or fail to confirm previously pub-
lished data, limitations due to experimental error cannot be accounted for. Some parameters
which are assumed to be equal in most laboratories are not. A mistake that is sometimes made
is to use a blocking solution that contains biotin with a primary or secondary antibody that is
covalently linked to biotin. Other examples include incorrect calculations for the amount of
antibody, incorrect buffer composition, dirty gel plates and gel boxes, and other components
used in Western blotting. Small amounts of SDS or other detergents left on the glass plates
used for gel electrophoresis have been shown to increase background [37]. The use of new
dishes for washing blots significantly decreases the background in Western blots. However,
these are likely to be only a small percentage of Western blots reported. Most scientists have
experienced the frustration of purchasing an antibody based on a publication and finding out
that the antibody does not work as advertised or that the antibody is unable to detect any pro-
teins. It is recommended that researchers do test blots using different buffers and antibody
dilutions to optimize for each Western carried out in the lab. In summary, as a scientific com-
munity we will only be able to reproduce and effectively utilize Western blotting data when we
have a basic set of reporting standards that allow the commonly used tricks and mistakes to be
well documented. Without improvements in the reporting of Western blotting data the
increasing number of poor quality antibodies currently available will likely further increase the
irreproducibility associated with Western blotting.
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